rongsheng jin brands

Currently, there is no efficient countermeasure for this toxin in case of a large outbreak of botulism, Jin said. Our discovery provides a vital first step toward a pharmaceutical intervention at an early point that can limit the toxins fatal attack on the human body.

Jin added that his work opens the door to further development of preventive treatments for botulism. At the same time, the molecular gateway for the lethal toxin could be exploited for alternative applications, such as the oral delivery of protein-based therapeutics.

Kwangkook Lee, Shenyan Gu and Guorui Yao of UC Irvine; Lei Jinof the Sanford-Burnham Medical Research Institute in La Jolla, Calif.; Thi Tuc Nghi Le, Jasmin Strotmeier and Anna Magdalena Kruelof the Institute for Toxicology at Germanys Hannover Medical School; Luisa W. Cheng of the U.S. Department of Agriculture; and Kay Perry of Cornell University contributed to the study, which was supported in part by the National Institute of Allergy & Infectious Diseases (grants R01AI091823 and U54 AI065359), the German Research Foundation, the Swiss Federal Office for Civil Protection and the U.S. Department of Agriculture CRIS project (grant 5325-42000-048-00D).

Aaron Chevalier*, Daniel-Adriano Silva*, Gabriel J. Rocklin*, Derrick R. Hicks, Renan Vergara, Patience Murapa, Steffen M. Bernard, Lu Zhang, Kwok-Ho Lam, Guorui Yao, Christopher D. Bahl, Shin-Ichiro Miyashita, Inna Goreshnik, James T. Fuller, Merika T. Koday, Cody M. Jenkins, Tom Colvin, Lauren Carter, Alan Bohn, Cassie M. Bryan, D. Alejandro Fernández-Velasco, Lance Stewart, Min Dong, Xuhui Huang, Rongsheng Jin, Ian A. Wilson, Deborah H. Fuller& David Baker.

“TcdB is one of two homologous C. difficile exotoxins, which are major virulence factors responsible for the spread of C. difficile infections,” said senior author Rongsheng Jin, PhD, a professor in the University of California–Irvine department of Physiology and Biophysics, in the press release. “TcdB alone is capable of causing the full spectrum of diseases associated with [Clostridioides difficile infection] in humans.

“What these new findings tell us is that a rationally designed CSPG4-mimicking decoy could neutralize major TcdB vairants, providing a unique therapeutic avenue for combating some of the hyper-virulent C. difficile strains,” Jin said in the press release.

“We have designed a CSPG4-mimicking decoy based on the 3D structure we observed,which could neutralize major TcdB variants and is superior to bezlotoxumab on a major TcdB variant from a hyper-virulent strain (TcdB2) in our studies,” Jin explained in the press release. “As a highly conserved cellular receptor of TcdB, a CSPG4 decoy molecule would be difficult for TcdB to escape, since any mutations that disrupt toxin binding to the decoy would also disrupt binding to its native receptors.”

“We are now examining the therapeutic features of these novel antitoxin molecules, and we believe they could provide broad-spectrum protection and neutralization against most known TcdB variants, thus improving existing antibody therapeutics for [Clostridioides difficile infection],” Jin concluded.

SMM9 March 28: today, Nanjing Rongsheng League Guli New Energy Technology Co., Ltd. solemnly held the opening ceremony of the annual 30GWh power battery project.

Rongsheng League Gouli New Energy Technology Co., Ltd. (referred to as "Rongsheng League Gouli") was established in May 2002. It is a high-tech enterprise specializing in the research, development and industrialization of lithium-ion power batteries for new energy vehicles, lithium-ion batteries for energy storage and key materials for lithium-ion batteries. It is the first power battery enterprise in the world to realize large-scale production and market-oriented application of large-capacity manganese lithium-ion batteries.

In order to promote the rapid, healthy and sustainable development of new energy vehicles as a strategic emerging industry, and adhere to the road of independent research and development, after more than ten years of unremitting efforts, Gouli of Rongsheng League has actively responded to the call of the national policy to promote the rapid, healthy and sustainable development of new energy vehicles, and has formed a core technology system with fully independent intellectual property rights. Manganese ternary lithium ion power battery and lithium titanate high power battery with excellent rate performance, long cycle life and reliable safety performance have been successfully developed, which have been widely used in the field of electric new energy vehicles in China. The market has been distributed all over the country.

The main products of Rongsheng League Couli are passenger car battery, bus battery, special vehicle battery, aircraft battery, energy storage battery and so on.

In terms of passenger car batteries, Rongsheng League Guri has reached in-depth cooperation with SAIC GM Wuling, Chery and BAIC New Energy to provide high-quality new energy passenger vehicle power lithium battery products.